I’m trying to decide if I will participate in the phase III clinical trial of FTY720. I need to decide now, even if the clinical trial should only begin in March. That’s because there must be a 3 month wash-out period (no interferon or glatiramer acetate) before the screening visit for the Phase 3 FTY720 study. I’ve been on Copaxone for 4.5 years but I had 2 relapses this year. Like most people here, I would love to be on a more effective medication than the current ABCR.
I already know that the phase II clinical trial had some good results and I am already aware of the potential benefits. I need you guys to help me out by briefly discussing the KNOWN risks of FTY720. I know that some new problems will probably emerge with more people taking the medication for a longer period of time and we will have a better idea of the risks vs benefits of this drug, like all others, at the end of the phase III trial.
I have some questions about the KNOWN risks of FTY720;
I read that 13 out of 1600 patients in the transplant group developed macular edema. I also read that they were taking a higher dose of FTY720 than the ms group (1.25mg and 5mg). I know that 5mg will not be used in the phase III clinical trial of multiple sclerosis (it had more side effects and didn’t seem to be much more effective). My question is the following; does anyone know how many mg of FTY720 the transplant group was taking?
Aside from macular edema, other unique side-effects seen with this medication were bradycardia and dyspnea. Any comments on these 2 possible side-effects?
I don’t think that there have been other serious side-effects reported so far aside from macular edema, bradycardia and dyspnea but if you have heard of anything else, I would love to hear about it.